Great Lakes Clinical Trials has initiated a new study to assess the effectiveness and safety of a new class of medication in migraine sufferers. This study is being conducted under the leadership of Great Lakes Clinical Trials' board-certified neurologist, John Lavaccare, MD and will begin enrolling patients on January 3rd.
You can learn more about this program on our study-specific web page by clicking here.